Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AtriCure (ATRC) EBIT (2016 - 2025)

AtriCure (ATRC) has disclosed EBIT for 16 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 117.15% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$9.4 million, a 76.39% increase, with the full-year FY2025 number at -$9.4 million, up 76.39% from a year prior.
  • EBIT was $2.5 million for Q4 2025 at AtriCure, up from $208000.0 in the prior quarter.
  • In the past five years, EBIT ranged from a high of $98.7 million in Q3 2021 to a low of -$15.9 million in Q1 2021.
  • A 5-year average of -$3.2 million and a median of -$7.7 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: surged 2572.29% in 2021, then tumbled 110.87% in 2022.
  • AtriCure's EBIT stood at -$12.5 million in 2021, then soared by 66.92% to -$4.1 million in 2022, then tumbled by 109.57% to -$8.7 million in 2023, then crashed by 67.55% to -$14.5 million in 2024, then surged by 117.15% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for ATRC's EBIT are $2.5 million (Q4 2025), $208000.0 (Q3 2025), and -$6.2 million (Q2 2025).